The first of four bellwether trials for the Xarelto multidistrict litigation (MDL) is set to begin on April 24, 2017, in the Eastern District of Louisiana. This trial was initially scheduled for February, but Righting Injustice reports U.S. District Judge Eldon Fallon and all parties agreed to push the trial back to March, due in part to New Orleans hosting the National Basketball Association (NBA) All Star Game during the same period. Ongoing discovery then resulted in the trial being rescheduled for April 24, 2017.

More than 15,680 U.S. lawsuits have been filed against the German drug manufacturer Bayer AG and Johnson & Johnson’s Janssen Pharmaceuticals, which sells the drug in the U.S. The Jere Beasley Report recently noted that 14,000 of those lawsuits are pending through the MDL in New Orleans.

Louisiana native Joseph Boudreaux’s case will be the first MDL trial and the first Xarelto trial in the nation. Mr. Boudreaux filed suit in December 2014 after using Xarelto for less than a month and suffering a severe gastrointestinal bleed that landed him in the hospital and forced him to endure several blood transfusions.

The U.S. Food and Drug Administration (FDA) first approved Xarelto in July 2011 to prevent blood clots following orthopedic surgery and to prevent strokes for patients with atrial fibrillation. In 2012, Xarelto was approved to treat deep vein thrombosis and pulmonary embolism.

Less than three years after Xarelto’s initial approval, the FDA issued black box warnings because of the Xarelto’s significant risk of severe, uncontrolled internal bleeding, which occurs most frequently in patients’ gastrointestinal tracts and brains. Unlike its predecessor warfarin, Xarelto does not have an antidote to reverse the blood thinning process. Moreover, Plaintiffs allege that the Defendants have mislead doctors in the U.S. regarding the ability to measure Xarelto’s effect on patients’ blood through laboratory testing.

* * *

Lawyers in Beasley Allen’s Mass Torts Section are investigating injuries suffered by patients who took Xarelto. Injuries include gastrointestinal, rectal and brain bleeds, and deaths caused by major bleeding events. If you would like more information, contact Joseph VanZandt, a lawyer in the Mass Torts Section. You can reach him at 800-898-2034 or by email at Joseph.Vanzandt@beasleyallen.com.

Sources:
Jere Beasley Report, December 2016
Righting Injustice



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

xarelto

Plaintiffs continue seeking justice over Xarelto...

Less than three years after Xarelto’s initial approval, the FDA issued black box warnings because of...
xarelto

New, contradictory evidence from Xarelto makers could...

There is an effective lab test to protect patients taking Xarelto, but that isn’t what jurors heard...
xarelto

Third Xarelto Trial Begins This Week

Last month, U.S. District Judge Eldon E. Fallon rejected the latest attempts by Xarelto makers to dodge...
xarelto

Recent studies confirm Xarelto bleeding risks, adverse...

There were 21,996 severe injuries reported involving anticoagulant drugs including 3,018 reported...
xarelto

Second Xarelto bellwether trial underway

The second bellwether trial involving bleeding risks with the blood thinner Xarelto is slated to begin...

Xarelto’s risks outweigh the benefits: Beasley Allen...

Xarelto is in a new class of blood thinners designed to be an alternative to warfarin for the treatment...

Wonderful to work with

Beasley Allen did a great job with my case. They were wonderful to work with. They were available by phone when I needed them, treated me with the utmost respect and worked hard on my behalf. If a need arises in the future, I would definitely call on them again.

—Geraldine